4.1 Article

Mixed Amphetamine Salts-Extended Release (MAS-ER) as a Behavioral Treatment Augmentation Strategy for Cocaine Use Disorder: A Randomized Clinical Trial

出版社

AMER PSYCHOLOGICAL ASSOC
DOI: 10.1037/pha0000676

关键词

computer-delivered therapy; contingency management; pharmacotherapy; adaptive intervention; relapse prevention

向作者/读者索取更多资源

Psychosocial interventions are the main approach for treating cocaine use disorder, but not everyone benefits from them. Amphetamine-based interventions show promise in improving outcomes for individuals who continue to use cocaine despite behavioral interventions.
Psychosocial interventions remain the primary strategy for addressing cocaine use disorder (CUD), although many individuals do not benefit from these approaches. Amphetamine-based interventions have shown significant promise and may improve outcomes among individuals continuing to use cocaine in the context of behavioral interventions. One hundred forty-five adults (122 males) who used cocaine a minimum of 4 days in the prior month and met the criteria for a CUD enrolled in a two-stage intervention. All participants received a computer-delivered skills intervention and contingency management for reinforcing abstinence for a 1-month period. Participants demonstrating less than 3 weeks of abstinence in the first month were randomized to receive mixed amphetamine salts-extended release (MAS-ER) or placebo (80 mg/day) for 10 weeks under double-blind conditions. All participants continued with the behavioral intervention. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence as measured by urine toxicology confirmed self-report at the study end. The proportion of participants demonstrating 3 consecutive weeks of abstinence at study end did not differ between the medication groups: MAS-ER = 15.6% (7/45) and placebo = 12.2% (5/41). Participants who received MAS-ER reported greater reductions in the magnitude of wanting cocaine, although no group differences were noted in either the perceived improvement or the frequency of wanting cocaine. Retention rates were greater for both medication groups compared to behavioral responders. Overall, augmenting a behavioral intervention with MAS-ER did not significantly increase the abstinence rate among individuals continuing to use cocaine following a month of behavioral therapy alone.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Substance Abuse

Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder

John J. Mariani, Martina Pavlicova, Cale Basaraba, Agnieszka Mamczur-Fuller, Daniel J. Brooks, Adam Bisaga, Kenneth M. Carpenter, Edward Nunes, Frances R. Levin

Summary: The pilot study showed that high-dose gabapentin was more effective in reducing harmful alcohol consumption and increasing percent days abstinent in actively drinking outpatients with AUD.

ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2021)

Article Substance Abuse

Non-abstinent treatment outcomes for cannabis use disorder

Frances R. Levin, John J. Mariani, C. Jean Choi, Cale Basaraba, Daniel J. Brooks, Christina A. Brezing, Martina Pavlicova

Summary: This study explores the feasibility of using reductions in self-reported days of cannabis use as a viable outcome measure for Cannabis Use Disorder treatment. The results showed that individuals on active medication were more likely to transition from heavy to moderate use towards the end of each trial, indicating that certain medications may have a greater impact than previously assessed. Future studies should further investigate if this pattern is associated with reduced CUD severity and/or improved quality of life.

DRUG AND ALCOHOL DEPENDENCE (2021)

Article Substance Abuse

Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl

John J. Mariani, Amy L. Mahony, Samuel C. Podell, Daniel J. Brooks, Christina Brezing, Sean X. Luo, Nasir H. Naqvi, Frances R. Levin

Summary: This study demonstrated the feasibility of inducing heroin-containing fentanyl users onto 300 mg BXR injection treatment in a single day, and all participants remained engaged in the study for the full 3 months post-induction. The ability to administer long-acting BXR injections that ensure therapeutic serum levels for a month on the first day of treatment contact is a promising development for OUD treatment.

AMERICAN JOURNAL ON ADDICTIONS (2021)

Article Health Care Sciences & Services

Patient Engagement With a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder: Protocol for a Randomized Controlled Open-Label, Decentralized Trial

Hilary Luderer, Lisa Chiodo, Amanda Wilson, Christina Brezing, Suky Martinez, Xiaorui Xiong, Robert Gerwien, Bruce Imbert, Mark Deeg, Yuri Maricich, Aimee Campbell

Summary: This study aims to investigate how participants interact with a new content delivery format of a prescription digital therapeutic for opioid use disorder. The study will evaluate treatment success, symptoms of co-occurring mental health disorders, recovery capital, and skill development. A decentralized, randomized controlled trial design will be utilized to compare patient engagement with the new digital therapeutic and the existing one. The results will provide insights into the effectiveness of the different digital therapeutics.

JMIR RESEARCH PROTOCOLS (2022)

Article Psychology, Clinical

Telehealth for opioid use disorder: retention as a function of demographics and rurality

Arthur Robin Williams, Shoshana V. Aronowitz, Christopher Rowe, Ryan Gallagher, Emily Behar, Adam Bisaga

Summary: This study analyzed 180-day and 365-day retention in the treatment of opioid use disorder (OUD) using a virtual telehealth platform in Pennsylvania and New York. The findings showed that telehealth services for buprenorphine had high retention rates regardless of geography or race/ethnicity. However, age differences indicated that some patients may benefit from more intensive services early in care.

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2023)

Article Substance Abuse

Open-label pilot of lorcaserin (a serotonin 2C-receptor agonist) for cannabis use disorder

Christina A. Brezing, Mohammad Sibai, C. Jean Choi, Souparno Mitra, John J. Mariani, Nasir Naqvi, Amy L. Mahony, Daniel Brooks, Martina Pavlicova, Frances R. Levin

Summary: This study tested the tolerability and effects of the 5HT2c agonist lorcaserin in patients with CUD. The medication was well tolerated in male patients, but not in females. The frequency of cannabis use significantly decreased in the participants.

JOURNAL OF SUBSTANCE USE (2023)

Article Psychology, Multidisciplinary

Environmental Cues Can Indirectly Acquire Cocaine-Eliciting Changes in Heart Rate: A Pilot Study of Derived Relational Responding, the Transfer of Function among Cocaine Users

Kenneth M. Carpenter, Richard W. Foltin, Margaret Haney, Suzette M. Evans

Summary: This study investigated how environmental stimuli can influence drug use and found that stimuli paired with smoked cocaine caused changes in heart rate among some participants. These findings have important implications for understanding how stimuli can trigger cocaine use and developing interventions for cocaine use disorder.

PSYCHOLOGICAL RECORD (2023)

Article Substance Abuse

Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs

John J. Mariani, Robert L. Dobbins, Amy Heath, Frank Gray, Howard Hassman

Summary: This study shows that rapid induction of extended-release buprenorphine treatment is feasible and well-tolerated for patients with opioid use disorder, regardless of their fentanyl use status. The results suggest comparable patient retention and clinical response following single-day induction of BUP-XR for patients who are fentanyl-positive and fentanyl-negative.

AMERICAN JOURNAL ON ADDICTIONS (2023)

Article Substance Abuse

Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users

John J. Mariani, Amy Mahony, Muhammad N. Iqbal, Sean X. Luo, Nasir H. Naqvi, Frances R. Levin

AMERICAN JOURNAL ON ADDICTIONS (2020)

暂无数据